Confo Therapeutics NV
Latest round
- Series B
Last raised
- Jul 2024
Total raised
- $57M
Investors
- 13
About Confo Therapeutics NV
Founded in 2015 and based in Brussels, Belgium, Confo Therapeutics, a spin-out from Vrije Universiteit Brussel (VUB) and VIB, is a biopharmaceutical company that develops GPCR (G-protein-coupled receptors) targeted therapeutics by leveraging its technology, ConfoBody. Confo Therapeutics specializes in the discovery and development of drugs targeting G protein-coupled receptors (GPCRs), the largest family of membrane proteins involved in numerous biological processes. The company’s core technology utilizes conformationally selective VHH antibodies, known as ConfoBodies®, to stabilize GPCRs, facilitating the design of novel therapeutic agents. ConfoBodies are camel single-domain antibodies that stabilize distinct druggable conformers of flexible protein targets and reveal previously inaccessible structural features. It also identifies the differentiating chemical series with the appropriate therapeutic mode of action. Confo will expand its portfolio of GPCR-targeting small molecules and therapeutic antibodies, which includes an emphasis on agonistic antibodies.
Who invested in Confo Therapeutics NV
13 investors across 2 rounds
See all investors in Confo Therapeutics NV
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Confo Therapeutics NV
Who invested in Confo Therapeutics NV?
Confo Therapeutics NV has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Confo Therapeutics NV raised?
Confo Therapeutics NV has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Confo Therapeutics NV last raise money?
Confo Therapeutics NV's most recent round on record is a Series B, in Jul 2024.
What does Confo Therapeutics NV do?
Founded in 2015 and based in Brussels, Belgium, Confo Therapeutics, a spin-out from Vrije Universiteit Brussel (VUB) and VIB, is a biopharmaceutical company that develops GPCR (G-protein-coupled receptors) targeted therapeutics by leveraging its technology, ConfoBody.
Where is Confo Therapeutics NV headquartered?
Confo Therapeutics NV is headquartered in Zwijnaarde, Belgium.
Which VCs invest in companies like Confo Therapeutics NV?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Confo Therapeutics NV's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Confo Therapeutics NV? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.